Insider Selling: Alphatec (NASDAQ:ATEC) EVP Sells 37,358 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig Hunsaker sold 37,358 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $14.71, for a total value of $549,536.18. Following the sale, the executive vice president owned 1,173,025 shares of the company’s stock, valued at approximately $17,255,197.75. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Alphatec Price Performance

Alphatec stock traded down $0.61 during midday trading on Wednesday, reaching $14.06. The company’s stock had a trading volume of 2,847,234 shares, compared to its average volume of 3,920,410. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The stock has a market cap of $2.09 billion, a PE ratio of -13.52 and a beta of 1.01. Alphatec Holdings, Inc. has a 52 week low of $8.81 and a 52 week high of $23.29. The business has a 50-day moving average price of $19.39 and a 200-day moving average price of $17.03.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ATEC. Loop Capital set a $25.00 price target on Alphatec in a research note on Wednesday, December 10th. Stifel Nicolaus initiated coverage on shares of Alphatec in a report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a research note on Friday, October 24th. They set an “overweight” rating and a $19.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 29th. Finally, Canaccord Genuity Group raised their target price on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.82.

Hedge Funds Weigh In On Alphatec

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in Alphatec during the third quarter worth approximately $34,000. Osterweis Capital Management Inc. acquired a new stake in Alphatec in the 2nd quarter valued at $37,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Alphatec in the 3rd quarter worth about $73,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Alphatec in the third quarter worth approximately $74,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.